Lyon Street Capital LLC bought a new stake in Tokai Pharmaceuticals, Inc. (NASDAQ:NVUS) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 40,766 shares of the biopharmaceutical company’s stock, valued at approximately $238,000. Lyon Street Capital LLC owned about 5.51% of Tokai Pharmaceuticals at the end of the most recent quarter.

Separately, Vanguard Group Inc. acquired a new position in shares of Tokai Pharmaceuticals in the second quarter valued at approximately $251,000. Institutional investors own 39.76% of the company’s stock.

Tokai Pharmaceuticals, Inc. (NASDAQ NVUS) traded down 2.99% during trading on Friday, hitting $4.87. The stock had a trading volume of 1,860 shares. The firm has a 50 day moving average price of $4.13 and a 200-day moving average price of $5.60. The firm’s market capitalization is $33.81 million. Tokai Pharmaceuticals, Inc. has a 1-year low of $3.42 and a 1-year high of $18.83.

Separately, Zacks Investment Research raised Tokai Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th.

ILLEGAL ACTIVITY WARNING: This piece was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at

Tokai Pharmaceuticals Profile

Novus Therapeutics, Inc, formerly Tokai Pharmaceuticals, Inc, is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities.

Receive News & Stock Ratings for Tokai Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tokai Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.